Matrix Metalloproteinase Inhibitors
"Matrix Metalloproteinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the enzyme activity or activation of MATRIX METALLOPROTEINASES.
| Descriptor ID |
D061965
|
| MeSH Number(s) |
D27.505.519.389.745.610
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Matrix Metalloproteinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Matrix Metalloproteinase Inhibitors".
This graph shows the total number of publications written about "Matrix Metalloproteinase Inhibitors" by people in this website by year, and whether "Matrix Metalloproteinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 1 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 5 | 3 | 8 |
| 2005 | 1 | 1 | 2 |
| 2006 | 3 | 0 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Matrix Metalloproteinase Inhibitors" by people in Profiles.
-
Targeted delivery of pentagalloyl glucose inhibits matrix metalloproteinase activity and preserves elastin in emphysematous lungs. Respir Res. 2021 Sep 18; 22(1):249.
-
Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging. Int Heart J. 2021 Sep 30; 62(5):1096-1105.
-
Plasma matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs and aging and lifelong exercise adaptations in ventricular and arterial stiffness. Exp Gerontol. 2019 08; 123:36-44.
-
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. J Med Chem. 2018 03 22; 61(6):2589-2603.
-
Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Prog Mol Biol Transl Sci. 2017; 147:75-100.
-
Pericytes as Inducers of Rapid, Matrix Metalloproteinase-9-Dependent Capillary Damage during Ischemia. J Neurosci. 2017 01 04; 37(1):129-140.
-
Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability. J Vasc Res. 2016; 53(1-2):1-16.
-
Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke. Stroke. 2016 Mar; 47(3):843-51.
-
Prevention of abdominal aortic aneurysm progression by targeted inhibition of matrix metalloproteinase activity with batimastat-loaded nanoparticles. Circ Res. 2015 Nov 06; 117(11):e80-9.
-
Matrix metalloproteinases and bronchiolitis obliterans: Wrapping the enigma in a riddle. J Thorac Cardiovasc Surg. 2015 Apr; 149(4):1203-4.